Today: 3 March 2026
Subscribe

Mateusz Kaczmarek

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

AI Chip Frenzy Sends Lam Research Soaring 117% – More Upside Ahead?

AI Chip Frenzy Sends Lam Research Soaring 117% – More Upside Ahead?

Lam Research shares have surged 117% year-to-date in 2025, far outpacing Nvidia and Broadcom. The company posted Q3 revenue of $5.32 billion, up about 28% year-over-year, and adjusted EPS jumped 46% to $1.26. Lam raised guidance for the next quarter, citing soaring demand for AI chipmaking equipment. CEO Tim Archer said AI data center investment is directly expanding Lam’s market.
3 November 2025
···
ClearPoint Neuro (CLPT) Stock Skyrockets on Brain Therapy Breakthroughs – 2025 Deep Dive

ClearPoint Neuro (CLPT) Stock Skyrockets on Brain Therapy Breakthroughs – 2025 Deep Dive

ClearPoint Neuro shares surged to the mid-$20s in November 2025 after hitting a 52-week high near $30, driven by heavy trading and recent product breakthroughs. The company reported Q2 revenue of $9.2 million, up 17% year-on-year, but remains unprofitable. Its neuro devices gained expanded FDA clearance and international approvals. Analysts maintain buy ratings with price targets averaging $29.
3 November 2025
·
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers said Oct. 29 it will offer clinician-supervised GLP-1 “microdose” plans using compounded semaglutide for metabolic health, priced at $1,200 for six months. The drugs, not FDA-approved, target patients with conditions like sleep apnea or high blood pressure. Medical experts warn safety data is limited and compounded versions carry risks. HIMS stock rose 2–3% after the announcement.
3 November 2025
···
CURE Pharmaceutical (CURR) Stock Skyrockets Amid Wellness Pivot – What’s Next for Investors?

CURE Pharmaceutical (CURR) Stock Skyrockets Amid Wellness Pivot – What’s Next for Investors?

CURE Pharmaceutical, now Avenir Wellness Solutions (AVRW), closed at $3.78 on Oct. 31, up 30.8% in one day and more than doubling over two weeks. The rally follows a settlement converting major debt to equity and anticipation of Nov. 18 earnings. The company rebranded in 2023 and focuses on wellness products. Technical signals warn of high volatility and potential pullback after the surge.
3 November 2025
·
Nocera (NCRA) Stock Skyrockets 36% on $300M Digital Asset Deal – Key Facts & Outlook

Nocera (NCRA) Stock Skyrockets 36% on $300M Digital Asset Deal – Key Facts & Outlook

Nocera, Inc. announced a private placement of up to $300 million in senior secured convertible notes to fund a stablecoin-based digital asset treasury and acquisitions. Shares surged as much as 36% pre-market on November 3, 2025, hitting a new 52-week high. The Taiwan-based firm, once focused on aquaculture, has shifted to an acquisition-driven model but remains unprofitable, with revenue down 29% in 2024.
3 November 2025
·
Dominion Energy’s Q3 Shocker: Data Center Boom and Offshore Wind Pay Off in Surging Profits

Dominion Energy’s Q3 Shocker: Data Center Boom and Offshore Wind Pay Off in Surging Profits

Dominion Energy reported Q3 2025 operating earnings of $1.06 per share, beating expectations, and GAAP net income rose to $1.0 billion from $934 million a year ago. Revenue jumped 15% to $4.53 billion, driven by strong power demand in Virginia and South Carolina. The company narrowed full-year guidance and is contracting to supply 47 GW of new data center capacity. Offshore wind project costs rose to $11.2 billion but remains on schedule.
3 November 2025
···
Biohaven Stock’s Wild Ride: Big Drops, Big Hopes as FDA Verdict Nears

Biohaven Stock’s Wild Ride: Big Drops, Big Hopes as FDA Verdict Nears

Biohaven Ltd. shares dropped over 20% in pre-market trading Nov. 3, falling to about $13.40 after closing at $17.20 on Oct. 31. The decline comes ahead of an FDA decision on troriluzole, expected in Q4 2025. The stock is down roughly 66% year-over-year, far underperforming biotech peers. Biohaven reported $408 million in cash mid-2025 but posted a $198 million net loss in Q2.
3 November 2025
·
Iovance Biotherapeutics (IOVA): TIL Cancer Breakthrough or Biotech Bust?

Iovance Biotherapeutics (IOVA): TIL Cancer Breakthrough or Biotech Bust?

Iovance shares traded near $2.00 on Nov. 3, 2025, with a market cap around $700 million after plunging 70% year-to-date. The company’s Amtagvi, the first FDA-approved TIL therapy for advanced melanoma, also secured Health Canada approval. Interim Phase 2 data showed a 25.6% response rate for lifileucel in advanced NSCLC. Iovance will hold its Q3 earnings call on Nov. 6.
3 November 2025
Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Phio Pharmaceuticals’ shares surged over 100% on November 3 after announcing positive Phase 1b results for its PH-762 skin cancer therapy, with one patient achieving full tumor clearance. No serious adverse effects were reported at any dose. The company, with a $12 million pre-rally market cap and no revenue, holds enough cash to fund operations into 2026 but will need more capital for larger trials. Analyst outlooks remain mixed.
3 November 2025
··
ON Semiconductor (ON) Stock Surges on Q3 Earnings Beat – Latest News, Financials, and Outlook

ON Semiconductor (ON) Stock Surges on Q3 Earnings Beat – Latest News, Financials, and Outlook

ON Semiconductor reported Q3 2025 net income of $255 million, or $0.63 per share, beating analyst estimates. Revenue reached $1.55 billion. The stock is down 10% year-to-date and 24% over 12 months, lagging sector gains. Analysts rate ON a “Moderate Buy,” with a $57–58 average price target, and expect a rebound in 2026 after a projected 42% EPS drop in 2025.
3 November 2025
··
UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure shares plunged nearly 65% to $23–24 midday Nov. 3 after the FDA ruled current Huntington’s trial data insufficient for approval, erasing billions in market value. The company had raised $345 million in September at $47.50/share following a surge on positive trial results. Q2 revenue was $5.3 million, with a net loss of $37.7 million. Cash reserves rose to about $550 million after the equity raise.
3 November 2025
··
MongoDB’s CEO Shake-Up: 11-Year Veteran Departs as Cloudflare Exec Takes Charge Amid Stock Surge

MongoDB’s CEO Shake-Up: 11-Year Veteran Departs as Cloudflare Exec Takes Charge Amid Stock Surge

MongoDB named Chirantan “CJ” Desai as its next CEO, replacing Dev Ittycheria, who will step down in November 2025 after 11 years. Shares jumped about 9% in pre-market trading, nearing all-time highs, as the company raised its Q3 FY2026 outlook and analysts boosted price targets. Ittycheria will stay on as an advisor during the transition. Final Q3 results are due December 1, 2025.
3 November 2025
····
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer shares traded at $24.65 on Nov. 3, 2025, down about 3% year-to-date and over 50% from pandemic highs. The company reports Q3 results Nov. 4, with analysts expecting $16.6 billion in revenue and $0.66 EPS. Pfizer completed a $43 billion Seagen acquisition and is in a bidding war with Novo Nordisk over Metsera. The quarterly dividend is $0.43 per share, yielding around 7%.
3 November 2025
··
Amazon Stock Skyrockets to Record High on AWS Boom – Analysts Predict More Upside

Amazon Stock Skyrockets to Record High on AWS Boom – Analysts Predict More Upside

Amazon shares hit a record high near $244 on Oct. 31, 2025, after surging almost 10% on strong Q3 results. Revenue reached $180.2 billion and net income jumped to $21.2 billion, boosted by a $9.5 billion gain from its Anthropic investment. AWS revenue grew 20% to $33 billion, easing cloud slowdown fears. Wall Street raised price targets, with some analysts now valuing Amazon near $300 per share.
3 November 2025
···
Opendoor Stock Skyrockets 1300% Amid Meme Hype – Will the Rally Survive the Housing Slump?

Opendoor Stock Skyrockets 1300% Amid Meme Hype – Will the Rally Survive the Housing Slump?

Opendoor Technologies shares surged 1,300% from June lows, averting Nasdaq delisting and prompting the company to cancel a planned reverse split. Despite the rally, Opendoor posted a $29 million Q2 loss and expects Q3 revenue to fall sharply. The company named Kaz Nejatian CEO in September, shifting focus to AI-powered real estate. Wall Street analysts remain skeptical, with price targets below current levels.
3 November 2025
··
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics shares jumped about 14% pre-market Nov. 3, 2025, trading near $2.27, down roughly 85% from its $12.50 IPO in 2022. Interim Phase 2b data for lead drug ACR-368 showed a 35% response rate in advanced endometrial cancer. The FDA granted Fast Track status to ACR-368 and Breakthrough Device designation to its companion diagnostic. Acrivon employs around 78 people in Watertown, MA.
3 November 2025
··
NIO Stock Skyrockets on Record Sales and Bold Moves – Can the Rally Last?

NIO Stock Skyrockets on Record Sales and Bold Moves – Can the Rally Last?

NIO delivered a record 40,397 vehicles in October 2025, up 92.6% year-over-year, pushing its stock to $7.25 after a sharp weekly rise. The company’s Onvo L90 SUV topped 10,000 units for a third month. NIO plans to expand into seven new European countries and hit 90 million battery swaps in October. Year-to-date, NIO shares are up about 60–66% but remain below 2021 highs.
3 November 2025
··
TGE Stock’s Wild Ride: Why The Generation Essentials Group Is Making Headlines in Nov 2025

TGE Stock’s Wild Ride: Why The Generation Essentials Group Is Making Headlines in Nov 2025

Generation Essentials Group (NYSE: TGE) stock plunged 54% to $0.78 on Oct. 31, 2025, then rebounded nearly 80% in early November. The company announced a $5 million share buyback and reported first-half 2025 revenue up 160% to $87.4 million. TGE holds $405 million in liabilities and faces tight liquidity, with analysts cautious and legal risks reported. The France-based media and hospitality firm went public via SPAC in mid-2025.
3 November 2025
·
1 … 48 49 50 51 52 … 140
Go toTop